RhumbLine Advisers’s Gyre Therapeutics GYRE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $119K | Buy |
16,186
+5,045
| +45% | +$37.1K | ﹤0.01% | 3472 |
|
|
2025
Q1 | $86K | Buy |
11,141
+709
| +7% | +$5.47K | ﹤0.01% | 3443 |
|
|
2024
Q4 | $126K | Buy |
10,432
+8
| +0.1% | +$97 | ﹤0.01% | 3404 |
|
|
2024
Q3 | $131K | Buy |
10,424
+133
| +1% | +$1.67K | ﹤0.01% | 3425 |
|
|
2024
Q2 | $123K | Buy |
+10,291
| New | +$123K | ﹤0.01% | 3453 |
|
|
2021
Q2 | – | Sell |
-4,398
| Closed | -$166K | – | 3045 |
|
|
2021
Q1 | $166K | Buy |
4,398
+440
| +11% | +$16.6K | ﹤0.01% | 2869 |
|
|
2020
Q4 | $187K | Buy |
3,958
+692
| +21% | +$32.7K | ﹤0.01% | 2859 |
|
|
2020
Q3 | $105K | Buy |
3,266
+371
| +13% | +$11.9K | ﹤0.01% | 2856 |
|
|
2020
Q2 | $127K | Buy |
+2,895
| New | +$127K | ﹤0.01% | 2915 |
|
|
2019
Q2 | – | Sell |
-2,243
| Closed | -$136K | – | 2983 |
|
|
2019
Q1 | $136K | Sell |
2,243
-24
| -1% | -$1.46K | ﹤0.01% | 2822 |
|
|
2018
Q4 | $134K | Buy |
2,267
+683
| +43% | +$40.4K | ﹤0.01% | 2836 |
|
|
2018
Q3 | $128K | Buy |
1,584
+35
| +2% | +$2.83K | ﹤0.01% | 2832 |
|
|
2018
Q2 | $136K | Buy |
+1,549
| New | +$136K | ﹤0.01% | 2834 |
|
|
2014
Q2 | – | Sell |
-48
| Closed | -$178K | – | 3032 |
|
|
2014
Q1 | $178K | Sell |
48
-1
| -2% | -$3.71K | ﹤0.01% | 2812 |
|
|
2013
Q4 | $161K | Sell |
49
-3
| -6% | -$9.86K | ﹤0.01% | 2885 |
|
|
2013
Q3 | $220K | Sell |
52
-1
| -2% | -$4.23K | ﹤0.01% | 2730 |
|
|
2013
Q2 | $178K | Buy |
+53
| New | +$178K | ﹤0.01% | 3039 |
|